Rachel Guerra

Title: Rachel Guerra: Innovator in Cancer Treatment

Introduction

Rachel Guerra is a prominent inventor based in Cambridge, MA, known for her significant contributions to cancer research and treatment. She has developed innovative solutions aimed at selectively targeting apoptosis proteins, which play a crucial role in cancer cell survival.

Latest Patents

Rachel Guerra holds a patent for "Selective targeting of apoptosis proteins by structurally-stabilized and/or cysteine-reactive NOXA peptides." This patent features structurally-stabilized and/or cysteine-reactive peptide inhibitors designed for the selective targeting of BFL-1, or dual targeting of BFL-1 and MCL-1. The disclosure also includes methods for using these peptides in treating BFL-1- and/or MCL-1-expressing or -dependent cancers, as well as diseases characterized by cellular excess, such as autoimmune or inflammatory conditions. Additionally, the patent outlines combination therapies that incorporate these peptides with inhibitors of the DNA damage response pathway, enhancing treatment efficacy for various cancers.

Career Highlights

Rachel Guerra is affiliated with the Dana-Farber Cancer Institute Inc., where she continues her research and development efforts. Her work is pivotal in advancing therapeutic strategies for cancer treatment, particularly in targeting specific proteins that contribute to cancer cell survival.

Collaborations

Some of her notable collaborators include Loren D. Walensky and Gregory H. Bird, who have worked alongside her in the field of cancer research.

Conclusion

Rachel Guerra's innovative work in developing peptide inhibitors represents a significant advancement in cancer treatment strategies. Her contributions are vital in the ongoing fight against cancer, showcasing the importance of targeted therapies in modern medicine.